Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension

   Completed · Phase 4 · Symptomatic Neurogenic Orthostatic Hypotension

   NCT02586623 · H. Lundbeck A S · 1 U.S. investigator

   $2,505research payments

2. Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409

   Completed · Phase 4 · Relapsing Remitting Multiple Sclerosis

   NCT02255656 · Genzyme Corporation · 0 U.S. investigators

   $2,500research payments

3. Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency

   Completed · Phase 1, Phase 2 · Sphingomyelin Lipidosis

   NCT02292654 · Genzyme Corporation · 0 U.S. investigators

   $2,500research payments

4. A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies

   Status unknown · Phase 1 · Hematologic Malignancies

   NCT03557619 · AbbVie Inc. · 1 U.S. investigator

   $2,500research payments

5. A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss

   Completed · Phase 3 · Obesity

   NCT04660643 · Eli Lilly and Company · 1 U.S. investigator

   $2,500research payments

6. Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis

   Terminated · Phase 3 · Adolescent Lupus Nephritis

   NCT05288855 · Aurinia Pharma U.S., Inc. · 2 U.S. investigators

   $2,492research payments

7. A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

   Completed · Phase 3 · Diabetes

   NCT05362058 · Eli Lilly and Company · 2 U.S. investigators

   $2,449research payments

8. A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

   Active, not recruiting · Phase 3 · Cardiomyopathy, Hypertrophic

   NCT06253221 · E.r. Squibb & Sons, L.l.c. · 3 U.S. investigators

   $2,392research payments

9. A Rapid Clinical Care Pathway to Care for Patients Affected by Chronic Constipation

   Completed · Not applicable · Constipation

   NCT07032376 · Neuraxis, Inc. · 1 U.S. investigator

   $2,360research payments

10. A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.

    Completed · Phase 3 · Fibrodysplasia Ossificans Progressiva (FOP)

    NCT05027802 · Ipsen Pharma Sas · 1 U.S. investigator

    $2,343research payments

11. Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

    Active, not recruiting · Phase 1 · Advanced Solid Tumor

    NCT03993873 · E.r. Squibb & Sons, L.l.c. · 1 U.S. investigator

    $2,340research payments

12. Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

    Completed · Phase 3 · Carcinoma，Non-Small-Cell Lung

    NCT03088540 · Regeneron Pharmaceuticals, Inc. · 0 U.S. investigators

    $2,275research payments

13. A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors

    Completed · Phase 3 · Hemophilia A

    NCT03417102 · Genzyme Corporation · 0 U.S. investigators

    $2,250research payments

14. A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

    Completed · Phase 1, Phase 2 · Cancer

    NCT03400332 · E.r. Squibb & Sons, L.l.c. · 1 U.S. investigator

    $2,213research payments

15. Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)

    Completed · Phase 2 · Allergic Bronchopulmonary Aspergillosis

    NCT04442269 · Regeneron Pharmaceuticals, Inc. · 0 U.S. investigators

    $2,185research payments

16. Comparison of the Atmo Motility Gas Capsule System to the Reference Standard

    Completed · Not applicable · Gastroparesis

    NCT05718505 · Atmo Biosciences Inc · 1 U.S. investigator

    $2,172research payments

17. A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis

    Completed · Phase 2 · Moderate to Severe Plaque Psoriasis

    NCT04718896 · UCB SA · 1 U.S. investigator

    $2,145research payments

18. An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)

    Terminated · Phase 2 · Alzheimer's Disease

    NCT03712787 · AbbVie Inc. · 1 U.S. investigator

    $2,128research payments

19. Mymobility Knee ROM

    Completed · Knee Range of Motion

    NCT06863428 · Zimmer Biomet Holdings, Inc. · 1 U.S. investigator

    $2,090research payments

20. Pharmacogenetic Variation: Factors That May Affect the Efficacy and Safety of Medical Marijuana

    Completed · New York Medical Marijuana Program Qualifying Conditions

    NCT04083261 · Ipsen Bioscience Inc. · 1 U.S. investigator

    $2,062research payments

21. The Mycophenolate Pregnancy Registry

    Completed · Heart Transplantation, Kidney Transplantation, Liver Transplantation, Autoimmune Diseases

    NCT01733082 · Mylan Inc. · 0 U.S. investigators

    $2,025research payments

22. First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors

    Terminated · Phase 1, Phase 2 · Advanced Cancer

    NCT03110107 · E.r. Squibb & Sons, L.l.c. · 1 U.S. investigator

    $2,000research payments

23. Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)

    Completed · Phase 3 · Neurodermatitis

    NCT04202679 · Genzyme Corporation · 0 U.S. investigators

    $2,000research payments

24. Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

    Terminated · Phase 2 · Acute Lymphoblastic Leukemia

    NCT03860844 · Sanofi US Services Inc. · 1 U.S. investigator

    $1,983research payments

25. Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

    Completed · Phase 3 · TNBC - Triple-Negative Breast Cancer

    NCT04799249 · Pharmacosmos Therapeutics Inc. · 0 U.S. investigators

    $1,975research payments

26. A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

    Completed · Phase 2 · Chronic Lymphocytic Leukemia

    NCT02141282 · AbbVie Inc. · 1 U.S. investigator

    $1,965research payments

27. A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)

    Completed · Phase 3 · Type 2 Diabetes

    NCT05963022 · Eli Lilly and Company · 4 U.S. investigators

    $1,942research payments

28. SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients

    Terminated · Phase 3 · Non-small Cell Lung Cancer Metastatic

    NCT04154956 · Sanofi US Services Inc. · 1 U.S. investigator

    $1,813research payments

29. A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

    Completed · Phase 3 · Ulcerative Colitis

    NCT03524092 · Eli Lilly and Company · 0 U.S. investigators

    $1,800research payments

30. An Open-label Study of Poly-l-lactic Acid for Correction of Wrinkles in the décolletage Area

    Completed · Not applicable · Wrinkles in Decolletage

    NCT05538728 · Galderma Laboratories, L.P. · 2 U.S. investigators

    $1,800research payments

31. CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease

    Terminated · Phase 1 · Anemia, Sickle Cell

    NCT04091737 · Csl Behring · 0 U.S. investigators

    $1,786research payments

32. Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder

    Completed · Phase 3 · CDKL5 Deficiency Disorder

    NCT03572933 · Immedica Pharma US, Inc. · 1 U.S. investigator

    $1,690research payments

33. Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People.

    Recruiting · HIV Infections

    NCT00404989 · Apotex Inc. · 0 U.S. investigators

    $1,662research payments

34. A Study of LY2784544 in Participants With Myeloproliferative Neoplasms

    Active, not recruiting · Phase 2 · Neoplasms, Hematologic

    NCT01594723 · Eli Lilly and Company · 1 U.S. investigator

    $1,652research payments

35. A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

    Recruiting · Phase 3 · CLL

    NCT06846671 · Beone Medicines Ltd. · 0 U.S. investigators

    $1,600research payments

36. A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors

    Active, not recruiting · Phase 3 · Chronic Lymphocytic Leukemia

    NCT06970743 · Beone Medicines Ltd. · 0 U.S. investigators

    $1,600research payments

37. JuggerStitch Post Market Clinical Follow-up Study

    Completed · Not applicable · Meniscus Tear, Tibial

    NCT04228367 · Zimmer Biomet Holdings, Inc. · 1 U.S. investigator

    $1,567research payments

38. A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)

    Completed · Phase 3 · Gaucher Disease, Type 1

    NCT00891202 · Genzyme Corporation · 0 U.S. investigators

    $1,500research payments

39. Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A

    Completed · Phase 3 · Hemophilia A

    NCT04759131 · Genzyme Corporation · 0 U.S. investigators

    $1,500research payments

40. Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines

    Completed · Phase 3 · Glabellar Frown Lines

    NCT05146999 · Galderma Laboratories, L.P. · 2 U.S. investigators

    $1,500research payments

41. A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants

    Completed · Phase 1 · Healthy Volunteers

    NCT06493409 · E.r. Squibb & Sons, L.l.c. · 1 U.S. investigator

    $1,500research payments

42. A Study of the Helix Surgical System in Primary Open-Angle Glaucoma (POAG) and Cataract (HELIX)

    Active, not recruiting · Not applicable · Primary Open Angle Glaucoma

    NCT06948773 · Sight Sciences, Inc. · 0 U.S. investigators

    $1,500research payments

43. A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors

    Recruiting · Phase 1 · Advanced Squamous Tumors

    NCT07241039 · AbbVie Inc. · 3 U.S. investigators

    $1,498research payments

44. IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)

    Completed · Phase 3 · Hypercholesterolemia

    NCT00202878 · Philips North America LLC · 2 U.S. investigators

    $1,430research payments

45. Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)

    Completed · Dermatitis Atopic

    NCT03849716 · Sanofi US Services Inc. · 3 U.S. investigators

    $1,418research payments

46. A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus

    Terminated · Phase 2 · Systemic Lupus Erythematosus

    NCT05123586 · Eli Lilly and Company · 1 U.S. investigator

    $1,413research payments

47. StrataGraft Overlay of Meshed Autograft in Full-thickness Thermal Burns

    Terminated · Phase 1, Phase 2 · Full Thickness Thermal Burn

    NCT04765202 · Mallinckrodt Hospital Products Inc. · 1 U.S. investigator

    $1,365research payments

48. Triathlon Tritanium Knee Outcomes Study

    Terminated · Not applicable · Arthroplasty, Replacement, Knee

    NCT02155712 · Stryker Corporation · 1 U.S. investigator

    $1,358research payments

49. Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites

    Recruiting · Phase 2 · Cirrhosis

    NCT06812390 · Grifols Shared Services North America, Inc. · 1 U.S. investigator

    $1,324research payments

50. A Study to Assess the Safety and Pharmacokinetics of a Single Dose of UCB9741 in Healthy Caucasian and Japanese Participants

    Completed · Phase 1 · Healthy Participants

    NCT06315335 · UCB SA · 0 U.S. investigators

    $1,314research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.